Abstract
Several non-coding microRNAs (miRs) are implicated in the pathogenesis of obesity, metabolic syndrome, diabetes mellitus, atherosclerosis and cardiovascular disease. Some of these miRs are beneficial but others are hazardous. Silencing of the latter by antisense oligonucleotides has been attempted in animal models with promising results. However, the replacement of down-regulated beneficial miRs, by manufactured miR mimics, or increasing their expression is much more demanding and has several limitations. The treatment of cardiovascular diseases through miR manipulation shows potential, provided safety and cost effectiveness issues are considered carefully before implementation in humans.
Keywords: microRNA, cardiovascular disease, obesity, metabolic syndrome, diabetes, antisense oligonucleotides, silencing, microRNA mimics.
Current Vascular Pharmacology
Title:Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Volume: 13 Issue: 3
Author(s): Vasilios G. Athyros, Niki Katsiki and Asterios Karagiannis
Affiliation:
Keywords: microRNA, cardiovascular disease, obesity, metabolic syndrome, diabetes, antisense oligonucleotides, silencing, microRNA mimics.
Abstract: Several non-coding microRNAs (miRs) are implicated in the pathogenesis of obesity, metabolic syndrome, diabetes mellitus, atherosclerosis and cardiovascular disease. Some of these miRs are beneficial but others are hazardous. Silencing of the latter by antisense oligonucleotides has been attempted in animal models with promising results. However, the replacement of down-regulated beneficial miRs, by manufactured miR mimics, or increasing their expression is much more demanding and has several limitations. The treatment of cardiovascular diseases through miR manipulation shows potential, provided safety and cost effectiveness issues are considered carefully before implementation in humans.
Export Options
About this article
Cite this article as:
Athyros G. Vasilios, Katsiki Niki and Karagiannis Asterios, Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/157016111303150707103801
DOI https://dx.doi.org/10.2174/157016111303150707103801 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Decrease in Serum Levels of Adiponectin and Increase in 8-OHdG: a Culprit for Cognitive Impairment in the Elderly Patients with Type 2 Diabetes
Current Molecular Medicine Natural Products as Modulators of Spermatogenesis: The Search for a Male Contraceptive
Current Molecular Pharmacology Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Structure – Function Relationships of Pre-Fibrillar Protein Assemblies in Alzheimers Disease and Related Disorders
Current Alzheimer Research In Search of Natural Remediation for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Meet Our Associate Editor
Current Cardiology Reviews Individual Differences and Vulnerability to Drug Addiction: A Focus on the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Does Metabolic Syndrome or its Individual Components Affect Pain and Function in Knee Osteoarthritis Women?
Current Rheumatology Reviews The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Metabolomic and Imaging: A Literature Review
Current Medical Imaging Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Markers of Early Vascular Ageing
Current Pharmaceutical Design Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation
Current Pharmaceutical Design SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews